R&D News | pharmaphorum

News

Lilly’s Taltz scrapes win against Humira in psoriatic arthri...

Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just.

News

Sobi cuts staff and buys Novimmune drug in refocus

Sobi has narrowed its focus to haematology and immunology, shedding staff and R&D projects in other areas whilst taking full control of a drug it licenses from Novimmune.

News

Novo Nordisk builds cardio claim case for oral semaglutide

Novo Nordisk’s bid to disrupt the diabetes market with an oral formulation of its GLP-1 agonist semaglutide has advanced again with new data showing it is safe for the heart.

News

Insys throws in the towel and files for bankruptcy

Insys has declared bankruptcy, hard on the heels of its agreement last week to a $225 million payment to settle charges it bribed doctors to prescribe opioid painkillers.

News

Merck bolts on another immunology firm with $773m Tilos deal

Merck & Co/MSD has agreed to buy privately held biotech Tilos Therapeutics for up to $773 million, its third pipeline-boosting deal in a little over four months.

News

Sanofi, Lilly and Novo make cases for diabetes drugs at ADA

The American Diabetes Association (ADA) annual conference has dominated the medical research headlines this weekend as pharma and biotech firms unveiled latest data from therapies for

Lilly’s Taltz scrapes win against Humira in psoriatic arthri...

Sobi cuts staff and buys Novimmune drug in refocus

Novo Nordisk builds cardio claim case for oral semaglutide

Insys throws in the towel and files for bankruptcy

Merck bolts on another immunology firm with $773m Tilos deal

Sanofi, Lilly and Novo make cases for diabetes drugs at ADA

FDA to decide on Takeda's psoriasis blockbuster hope in Q1

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks